Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
LE

NASDAQ · LEXX

Lexaria Bioscience Corp.

Healthcare · Biotechnology

$4.07

Up+$0.04 (+0.99%)

Updated Nov 5, 2026, 2:06 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
22.39M
P/E ratio
-1.99
Dividend yield
0.00%
52-week range
$0.52 – $14.37
Volume
32.33K
Avg. volume
572.75K

Price performance · LEXX

LEXX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

LEXX closed at $4.07 after 21 trading sessions, up 17.63% for the selected period.

Last close
$4.07
Period change
+17.63%
Period low
$2.60
Period high
$4.07
Daily close
View OHLC price history
LEXX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$4.01$4.30$3.875$4.0732.33K
Nov 3, 2026$3.79$4.10$3.70$4.0332.03K
Nov 2, 2026$3.50$3.96$3.445$3.6423.92K
Oct 30, 2026$3.63$3.63$3.09$3.4937.9K
Oct 29, 2026$3.38$3.87$3.30$3.7739.29K
Oct 28, 2026$3.13$3.55$3.065$3.3038.93K
Oct 27, 2026$2.91$3.31$2.91$3.2243.07K
Oct 26, 2026$3.08$3.08$2.83$2.9213.83K
Oct 23, 2026$2.98$3.1992$2.84$3.0823.23K
Oct 22, 2026$2.74$3.00$2.5101$2.9916.56K
Oct 21, 2026$2.68$2.89$2.5157$2.8228.67K
Oct 20, 2026$2.60$2.68$2.46$2.6542.02K
Oct 19, 2026$2.79$2.85$2.4301$2.6045.35K
Oct 16, 2026$3.19$3.24$2.81$2.86128.06K
Oct 15, 2026$2.74$3.1099$2.74$2.9938.66K
Oct 14, 2026$2.81$2.9195$2.43$2.82103.88K
Oct 13, 2026$3.29$3.29$2.69$2.80118.05K
Oct 12, 2026$3.18$3.6235$3.18$3.2766.14K
Oct 9, 2026$3.31$3.90$3.12$3.32200.68K
Oct 8, 2026$3.50$3.6693$3.19$3.2026.5K
Oct 7, 2026$3.14$3.59$3.10$3.4676.93K

Latest LEXX news

The latest Smart Investors Daily articles mentioning LEXX.

Stock researchCompany · Overview

LEXX research

Overview

Company profile and research snapshot.

Company profile

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
LEXX recent ratings
DateFirmRatingTarget
Dec 26, 2025HC Wainwright & Co.Buy—
Jul 29, 2025HC Wainwright & Co.Buy—
Jul 1, 2025HC Wainwright & Co.Buy—
Jan 24, 2025HC Wainwright & Co.Buy—
Dec 2, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Lexaria Celebrates its 70th Patent Award

* New patents awarded in the US, Canada, and Europe * IP protection for treatments for Epilepsy, Diabetes, and HypertensionKELOWNA, BC / ACCESS Newswire / October 28, 2026 / (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP") granted to the Company as a result of its ongoing research and development ("R&D") programs. The expansion of our IP is recognized and achieved, in part, t

Yahoo · Oct 21, 2026

Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

KELOWNA, BC / ACCESS Newswire / October 21, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study 7 (GLP-1-H26-7) which is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo's® commercially available Wegovy® tablets, over a 5-week duration (the "Study").The final Study arm was fully enrolled and began dosing, as schedule

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By